Calorie restriction and synbiotics effect on quality of life and edema reduction in breast cancer-related lymphedema, a clinical trial by Vafa, S. et al.
lable at ScienceDirect
The Breast 54 (2020) 37e45Contents lists avaiThe Breast
journal homepage: www.elsevier .com/brstCalorie restriction and synbiotics effect on quality of life and edema
reduction in breast cancer-related lymphedema, a clinical trial
Saeideh Vafa a, Mitra Zarrati a, **, Marjan Malakootinejad a, Ali Saneei Totmaj a,
Farid Zayeri b, Masoud Salehi c, Vahid Sanati a, Shahpar Haghighat d, *
a Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
b Proteomics Research Center and Department of Biostatistics, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
c Department of Biostatistics, School of Public Health, Health, Iran University of Medical Sciences, Tehran, Iran
d Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Irana r t i c l e i n f o
Article history:
Received 5 June 2020
Received in revised form
24 July 2020
Accepted 16 August 2020






Quality of life* Corresponding author.
** Corresponding author.
E-mail addresses: zarrati_ms@yahoo.com (M. Za
com, haghighat@acecr.ac.ir (S. Haghighat).
https://doi.org/10.1016/j.breast.2020.08.008
0960-9776/© 2020 The Author(s). Published by Elsevie
).a b s t r a c t
Background: Little evidence exists regarding the clinical value of synbiotics in the management of post-
treatment complications of breast cancer especially breast cancer-related lymphedema (BCRL). This
study aimed to investigate the effects of synbiotic supplementation along with calorie restriction on
quality of life and edema volume in patients with BCRL.
Methods: This randomized, placebo-controlled, clinical trial was conducted on 135 overweight and obese
women with BCRL aged 18e65 years old. Participants were randomly allocated to receive a calorie-
restricted diet plus 109 CFU synbiotic supplement (CRS group; n ¼ 45) or placebo (CRP group;
n ¼ 45), daily for 10 weeks. Also, a control group (n ¼ 45) with no intervention was included in the trial.
All of the participants received Complete Decongestive Therapy for lymphedema treatment. The quality
of life score, edema volume and body mass index (BMI) were measured at baseline and end of the trial.
Results: A total of 121 subjects completed the trial. CRS group showed a significant decrease in the total
quality of life score (P ¼ 0.004), and it’s psychosocial (P ¼ 0.022) and functional (P ¼ 0.002) domain
scores, as well as edema volume (P ¼ 0.002) and BMI (P < 0.001) in comparison to the control. However,
there were no significant differences in changes in trial outcomes between the CRS and CRP groups.
Conclusion: Synbiotic supplementation along with a low-calorie diet was effective in quality of life,
edema volume, and BMI improvement; mostly due to low-calorie diet. It seems that adding a dietitian
consultation on the lymphedema management strategy may provide a better result in lymphedema
control.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer is the second most common cancer and the fifth
leading cause of cancer deaths worldwide [1]. In 2018, 2.1 million
new cases of breast cancer were identified worldwide, which this
figure is anticipated to reach about 3.2 million by 2050 [2,3].
Notably, there has been an increasing trend in the survival of pa-
tients with breast cancer over recent years as a 5-year survival rate
is reported at 89% between 2005 and 2011 [4]. However, therrati), sha_haghighat@yahoo.
r Ltd. This is an open access articlecomplications related to the treatment, particularly the lymphe-
dema remains a challenge for patients with breast cancer.
Breast cancer-related lymphedema (BCRL) occurs as a result of
obstruction of lymphatic vessels that drain fluid from tissues
throughout the body, accumulation of protein-rich fluid in the
interstitial space, and consequently swelling of the arm, shoulder,
hand, breast, and/or trunk [5]. This complication is estimated to
affect about 20% of patients following the treatment, accounting for
more than one in five breast-cancer survivors [6]. It can exert an
adverse impact on various aspects of quality of life including
physical wellbeing (i.e. severity of pain, arm tightness, and heavi-
ness associated with lymphedema and impaired swollen arm/limb
function), psychosocial wellbeing (i.e. the person’s ability in the
perception of feelings, and socializing with others), and functional
wellbeing (i.e. the person’s ability to perform the daily activitiesunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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Besides the treatment-related risk factors (e.g. extensive lymph
node dissection and adjuvant chemo/radiation therapy), several
other factors such as overweight and obesity have been suggested
to could increase the risk of development of BCRL [8]. The mech-
anisms behind the pathogenesis of BCRL are still under investiga-
tion. However, the accumulating evidence suggests that chronic
inflammation might be a key contributor to the development of
BCRL through the formation of collateral lymphatic vessels, which
is regulated by inflammatory cytokines and growth factors [9].
Therefore, using adjuvant therapies that target the inflammation,
might be a good approach in the management of BCRL. Earlier
studies have well established the role of dietary modifications such
as restricted-calorie diets, focusing on weight loss/maintenance as
a major component of BCRL treatment [10,11]. Also, another factor
that has recently been highlighted in the literature is synbiotics.
Synbiotics refer to the combination of pro- and prebiotics in the
form of synergism [12]. Probiotics are certain viable microorgan-
isms, that can confer health benefits on the host when adminis-
tered in adequate dosage [13]. In comparison, prebiotics is
nonviable food components that can modulate the composition of
gut microbiota resulting in the host’s wellbeing [14]. Together, the
stimulation of probiotics with prebiotics could exert a superior
health effect in comparison to the single administration [12].
Recent studies show that the microbiota of women with breast
cancer differs from that of healthy women, indicating that certain
bacteria may be associated with different responses to therapy
[15e17]. Also, some evidence has shown that synbiotic supple-
mentation is accompanied by favourable changes on markers of
inflammation and oxidative stress and also, increasing the activity
of antioxidant enzymes in BCRL patients [18,19]. This might be due
to their ability to maintain the balance of the intestinal microbiota,
regulate the immunomodulatory responses as well as suppression
of the potential pathogens, and the inhibition of carcinogenesis
[12,16,17]. Since elevated inflammation and oxidative stress are
associated with impairment of quality of life [20e24], thus, using
synbiotics might be promising in improving the quality of life in
patients with BCRL.
Current evidence regarding the efficacy of synbiotic supple-
mentation on quality of life in patients with cancer, especially
breast cancer survivors is limited. With this regard, the present
clinical trial aimed to investigate the effect of synbiotic supple-
mentation along with a low-calorie diet on the quality of life in
BCRL patients. We hypothesized that co-administration of synbiotic
and low-calorie diet may exert a synergic effect and could
contribute to a more considerable improvement in the quality of
life in comparison to the low-calorie diet alone.
2. Methods
2.1. Study Design and subjects
This parallel, randomized, placebo-controlled, clinical trial was
performed on 121 BCRL women. Inclusion criteria were age 18e65
years old with body mass index (BMI) between 25 and 35 kg/m2,
who had been diagnosed with unilateral arm lymphedema at stage
I or II, at least six months passed from surgery and adjuvant therapy
completion (except hormone therapy/aromatase inhibitors) and
were treated by Complex Decongestive Therapy (CDT) in the Seyed-
Khandan Lymphedema Clinic (Tehran, Iran), between October 2017
and February 2018. CDT was achieved in two phases. In the
“intensive phase,” the swollen arm was decongested daily by a
Lymphotherapist for at least two weeks, using the manual lymph
drainage and multi-layer compression bandaging in the clinic. The
“maintenance phase” was achieved by the patient and family athome to stabilize edema reduction [25]. This study was performed
in themaintenance phase to evaluate the effect of the interventions
on changing arm volume.
Subjects were not included in the trial if they had at least one of
the following conditions: a history of any chronic or acute diseases
including cardiovascular, renal, pulmonary, and inflammatory dis-
eases as well as diabetes, autoimmune, thyroid and psychological
disorders; a history of smoking or alcohol consumption; taking any
nutritional supplements and/or probiotic supplements over the
three months before the intervention; following the weight-loss
diets during the last six months; having lymphedema due to
other cancers or diseases. Moreover, the exclusion criteria during
the intervention were as follows: breast cancer recurrence or
metastasis; intolerance or allergy to synbiotic or placebo supple-
ments or reporting any unexpected adverse effects; the presence of
any illness during the study, which requires the special treatments;
compliance to the supplementation less than 80% at the end of trial;
intake of any probiotic- and/or synbiotic-fortified foods during the
intervention; and unwillingness to continue the study.
2.2. Sample size
In 2017, the mean value of Quality of Life impairment in Iranian
lymphedema patients had been reported by 0.38 ± 0.22 [26].
Considering the standard deviation of 0.22, type I error of 5%, type II
error of 20%, and effect size of 0.16 due to synbiotic treatment, the
sample size was calculated 29 patients in each group. To study
between three groups’ correlation, the correction coefficient of 1.4
was multiplied by the estimated sample size, and it was increased
to 41 patients. Thus, the researchers decided to recruit 45 patients
in each group to compensate for the probability of a 10% loss to
follow up.
2.3. Study design
At the time of enrollment, all participants were advised to avoid
from consumption of any food or supplements containing pro-
biotic/synbiotic in 2 week run-in period and during the entire
study.
Participants were assigned to receive either a calorie-restricted
diet plus a synbiotic (CRS group) or a calorie-restricted diet plus a
placebo (CRP group) for ten weeks. Also, a control group that
received no interventionwas included in the study. To avoid control
contamination, all recruited patients were randomly allocated to
CRS and CRP groups using the balanced block randomization
method with a block size of 4. The allocation was performed using
software-generated random numbers, which was provided by an
academic member who was not associated with the study. After
completion of the sample size in two intervention groups, all par-
ticipants recruited into the control group.
Patients in the CRS and CRP groups were instructed to take one
capsule of either synbiotic or placebo per day, preferably after the
main meal. Synbiotic capsules consisted of 109 CFU/g of seven
probiotic strains including Lactobacillus casei, Lactobacillus aci-
dophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifido-
bacterium breve, Bifidobacterium longum, and Streptococcus
thermophiles, and 38.5 mg fructooligosaccharides (as prebiotic).
While, the placebo capsule was comprised of lactose and was equal
with the synbiotic capsule in terms of appearance, color, shape,
size, smell, taste, and packaging. All capsules were produced by Zist
Takhmir Co., Tehran, Iran, and were approved by the Food and Drug
Administration. Participants were instructed to keep the box of
capsules in the refrigerator and take them daily after meals for ten
weeks. Both the study participants and personnel were blinded to
the type of supplementation that patients received. Compliance
S. Vafa et al. / The Breast 54 (2020) 37e45 39with the consumption of capsules was monitored once a week
through phone calls. After five weeks of the study, participants
were revisited, and their diet, study compliance, and adverse events
were evaluated.
Furthermore, a low-calorie diet plan was prescribed for each
patient in the CRS and CRP groups, that based on age, baseline
weight, height, and the subject food records (using 24-h dietary
recalls for three days) they would have about 0.5e1 kg weight loss
per week. No participant was recommended a daily intake
<1200 kcal and their diets were changed after five weeks of the
study.
The energy requirement of participants was calculated based on
the Mifflin formula and the recommended energy content for each
macronutrient-based on American Cancer Society guidelines. It
consisted of 55%e65% of calories from carbohydrates, 10%e15%
from proteins, and 20%e35% from fats [27].
2.4. Outcomes
The primary outcome of this study was differences in quality of
life score following the synbiotic supplementation along with a
low-calorie diet, while the differences in edema volume and BMI
were the secondary outcomes. All measurements were conducted
at baseline and end of the trial.
2.4.1. Assessment of quality of life
Lymphedema Life Impact Scale (LLIS) questionnaire was used to
assess the quality of life in the lymphedema patient. The ques-
tionnaire comprises 18-item, which evaluates the physical (pain,
heaviness, tightness, strength …), psychosocial (body image, so-
cializing, intimate relations …) and functional (duties at home,
duties at work, recreational activities …) concerns related to lym-
phedema. Physical, psychosocial, and functional subscales consist
of 8, 4, and 6 items, respectively. Items are scored based on a five-
point Likert scale ranging from 1 (no impairment) to 5 (severe
impairment), and the total score is obtained by summing up all
items’ scores. The total and each subscale scores are a percentage
ranging from 0 to 100, in which higher percent of impairment in-
dicates the lower quality of life due to lymphedema. The validity
and reliability of the Persian version of LLIS were reported to be
acceptable in BCRL patients in Iran [28].
2.4.2. Assessment of edema volume
The volume of edema was measured using the water displace-
ment method (Submerging the affected limb after the healthy limb
in a water tank up to 2 cm below the armpit) [29]. Water overflow
was measured in milliliters in a graduated cylinder [30]. The vol-
ume of the limb was measured as the volume difference between
affected and healthy arms.
2.4.3. BMI measurement
Weight was measured using a Seca scale (Seca co., Hamburg,
Germany) as the patients were minimally clothes, barefoot, and in
standing position. Height was measured by a Seca stadiometer
(Seca co., Hamburg, Germany). Body mass index (BMI) was calcu-
lated as weight (kg) divided by height squared (cm2).
2.4.4. Assessment of diet and physical activity
Dietary intake of participants was collected using 24-h dietary
recalls for three nonconsecutive days (2 weekdays and one week-
end day) at baseline and after tenweeks of intervention. The intake
of energy, macro- and micro-nutrients were analyzed using
Nutritionist IV software (First Data Bank; Hearst Corp, San Bruno,
CA, USA). Also, physical activity level was determined by the In-
ternational Physical Activity Questionnaire (IPAQ), and it wasreported as metabolic equivalent per minute per week (MET-mi-
nutes/week) [31].
2.5. Statistical analysis
In the descriptive analysis, data with normal distribution were
reported as mean and standard deviation, while those with non-
normal distribution were presented as the median and inter-
quartile range (IQR). The outcome of interests was quality of life
score, BMI, and edema volume. KolmogoroveSmirnov test showed
non-normal distribution in quality of life score and edema volume
variables, and So, One-way analysis of variance (ANOVA) and
analysis of covariance (ANCOVA) was applied for comparison of
those variables between the trial arms. BMI variable had normal
distributions, so its difference between groups was studied by the
KruskaleWallis test.
In the case of BMI and quality of life score variables, which
showed significant differences (P < 0.05), Bonferroni correctionwas
performed to detect the significance of changes between the study
groups (two-sided a ¼ 0.05/3 ¼ 0.016). Also, the Chi-square test or
Fisher’s exact test was used for between-group comparison of the
categorical data such as chemotherapy, radiotherapy, breast cancer
stage at diagnosis, surgery type, estrogen status, progesterone
status, HER2 status, lymphedema stage, homogeneity of hands.
Furthermore, the within-group changes of outcomes were assessed
using the paired sample t-test or its non-parametric equivalent
(Wilcoxon signed-rank) test. Those statistical analyses were per-
formed using SPSS version 24 (IBM SPSS, Armonk, NY: 2016).
Finally, the marginal modelling with generalized estimating
equations (GEE) approach was employed to compare the mean
trend of quality of life, edema volume, and BMI between the
intervention arms and control group, adjusting for covariates
(baseline BMI, percentage change BMI, and edema volume). Also, to
compare the mean trend of outcomes between two intervention
arms (CRS and CRP groups), a contrast analysis was used. The
marginal modelling process was performed using the SAS software,
version 9.4.
3. Results
As it is shown in the study flow diagram (Fig. 1), Of the total of
135 subjects that were randomly allocated to the interventions and
control groups, 14 patients were excluded during the follow-up
interval due to the following reasons: long distance from resi-
dence to the clinic (n¼ 6); recurrent disease (n¼ 1); follow-upwith
other physicians (n ¼ 3); and unwillingness to continue the study
(n¼ 4). Thus, data on 121 subjects were included in the analysis. No
adverse effect was reported by study participants following the
intake of synbiotic and placebo capsules.
The baseline clinical characteristics of the study subjects have
been shown in Table 1. The study groups had a nearly similar dis-
tribution in terms of the most demographic and clinical features
except the proportion of patients with a history of radiotherapy
which was higher in the CRS group rather than the other two
groups (P¼ 0.019). Because radiation therapy does not have a direct
correlation with studied outcomes, it was not adjusted in GEE
analysis. However, the distribution of other clinical featureswas not
significantly different between the study groups.
Dietary energy and nutrients intake have been summarized in
Table 2. The mean intakes of total energy and sodium were
significantly different between the study groups at baseline
(P¼ 0.039; P < 0.001, respectively), whichwas adjusted for baseline
values of variables in ANCOVA analysis. Also, there were significant
differences in the intake of energy (0.024), carbohydrates
(P ¼ 0.026), protein (P ¼ 0.008), and sodium (P < 0.001) between
Fig. 1. CONSORT diagram for randomized controlled dietary intervention.
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Table 3 shows the changes in LLIS, edema volume, and BMI
between baseline measurements and after ten weeks of interven-
tion in CRS, CRP, and control groups. There were no significant
differences in these variables between the study groups at baseline,
except in BMI (P ¼ 0.014) and Psychosocial LLIS (0.029). Even
though Bonferroni correction of Post hoc analysis showed no sig-
nificant difference between the study groups for BMI and Psycho-
social LLIS at baseline, BMI was considered an important
confounder of outcomes, and its effect was adjusted in GEE
analysis.After ten weeks intervention period, the median values of the
total (P ¼ 0.001), physical (P < 0.001), psychosocial (P ¼ 0.001), and
functional (P ¼ 0.006) LLIS scores showed a significant difference
between CRS and control group. Also, the CRP group was signifi-
cantly different from the control group in total (P ¼ 0.001), psy-
chosocial (P < 0.001), and functional (P ¼ 0.001) LLIS Scores at the
end of the study.
The P-values of total, physical, psychosocial, and functional LLIS
percent changes between the three groups were 0.002, 0.026,
0.056, and 0.007, respectively. Post hoc analysis showed that the
significant correlation in physical subscales was due to the median
Table 1
Baseline clinical characteristics of study participants.
Study groups P-value
CRS (n ¼ 41) CRP (n ¼ 39) Control (n ¼ 41)
Mean ± SD Mean ± SD Mean ± SD
Age (years) 53.80 ± 1.42 52.41 ± 1.19 53.24 ± 1.5 0.736a
Physical activity (MET-minutes/week) 369.42 ± 194.37 342.24 ± 187.45 426.19 ± 234.40 0.182a
Time since cancer treatment (years) 5.43 ± 1.09 3.34 ± 3.7 3.66 ± 7.5 0.401a
Tumor size (cm) 3.19 ± 03 3.24 ± 0.34 2.65 ± 0.19 0.527a
CDT course numbers 15.66 ± 0.5 15.09 ± 0.5 14.24 ± 0.5 0.207a
Number (%) Number (%) Number (%)
Chemotherapy 39 (%95.1) 37 (%94.9) 40 (%97.6) 0.847b
Radiotherapy 41 (%100) 35 (%89.7) 34 (%82.9) 0.026b
Homogeneity of hands 19 (%46.3) 22 (%56.4) 21 (%51.2) 0.566b
Lymphedema stage 0.690b
I 6 (%14.6) 8 (%20.5) 7 (%17.1)
II 35 (%85.4) 31 (%79.5) 33 (%80.5)
Surgery type 0.331b
Mastectomy 26 (%63.4) 26 (%66.7) 20 (%48.8)
Lumpectomy 15 (%36.6) 13 (%33.3) 21 (%51.2)
Breast cancer stage at diagnosis 0.616b
I 3 (%7.3) 4 (%10.3) 1 (%2.4)
II 32 (%78) 28 (%71.8) 31 (%75.6)
III 6 (%14.6) 7 (%17.9) 9 (%22)
Estrogen status 0.700b
Positive 30 (%73.2) 31 (%79.5) 31 (%75.6)
Negative 11 (%26.8) 8 (%20.5) 10 (%24.4)
Progesterone status 0.648b
Positive 31 (%75.6) 27 (%69.2) 28 (%68.3)
Negative 10 (%24.4) 12 (%30.8) 13 (%31.7)
HER2 status 0.752b
Positive 9 (%22) 7 (%17.9) 6 (%14.6)
Negative 32 (%78) 32 (%82.1) 35 (%85.6)
Note: CRS group refers to the subjects received a calorie-restricted diet plus synbiotic, while CRP group followed a calorie-restricted diet plus placebo.
Abbreviations SD, standard deviation; MET, metabolic equivalent; CDT, complete decongestive therapy; HER2, human epidermal growth factor receptor 2.
a Obtained from one-way ANOVA.
b Obtained from Chi-square or Fisher exact test.
Table 2
Dietary intakes of participants throughout the trial.
Study groups P-value a
CRS (n ¼ 41) CRP (n ¼ 39) Control (n ¼ 41)
Mean ± SD Mean ± SD Mean ± SD
Energy (kcal/d) Baseline 2941.81 ± 349.09 3013.97 ± 329.68 2651.75 ± 183.88 0.058
End of trial 2537.39 ± 429.39 2562.89 ± 468.33 2779.02 ± 395.26 0.024
P-value b <0.001 <0.001 0.076
Carbohydrate (g/d) Baseline 348.84 ± 57.99 349.81 ± 75.23 347.49 ± 40.26 0.984
End of trial 308.82 ± 54.29 325.67 ± 58.73 340.88 ± 45.16 0.026
P-value b <0.001 <0.001 0.135
Protein (g/d) Baseline 118.66 ± 37.77 132.63 ± 45.54 120.27 ± 12.81 0.134
End of trial 100.08 ± 21.35 110.88 ± 44.03 120.88 ± 17.24 0.008
P-value b <0.001 0.236 0.662
Fat (g/d) Baseline 135.73 ± 204.20 143.15 ± 103.90 112.53 ± 20.60 0.123
End of trial 124.41 ± 52.68 122.50 ± 85.74 122.78 ± 34.83 0.872
P-value b 0.659 0.247 0.571
Sodium (mg/d) Baseline 1627.44 ± 793.14 1430.79 ± 509.92 1696.68 ± 181.47 <0.001
End of trial 1523.15 ± 815.81 1379.86 ± 490.69 2035.96 ± 193.06 <0.001
P-value b 0.336 0.002 0.011
Potassium (mg/d) Baseline 4828.65 ± 1728.52 5240.36 ± 1710.64 4846.07 ± 918.61 0.359
End of trial 4561.09 ± 1626.52 4986.15 ± 1572.50 4902.14 ± 871.15 0.353
P-value b 0.242 0.260 0.039
Note: CRS group refers to the subjects received a calorie-restricted diet plus synbiotic, while CRP group followed a calorie-restricted diet plus placebo for ten weeks.
Abbreviations: SD, standard deviation.
a Obtained from ANCOVA test adjusted for baseline values of variables.
b Obtained from Paired sample t-test.
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vs 19.23 P ¼ 0.005). Percent change of functional LLIS than the
control in the CRP (25% vs. 10%; P ¼ 0.014) and CRS (36.36%vs. 10%; P ¼ 0.005) groups decreased significantly. Also total
quality of life impairment compared to the control in CRS (39.53%
vs. 1.58% P ¼ 0.001) and CRP (28.57% vs. 1.58% P ¼ 0.011)
Table 3
The effects of the intervention on main variables before and after study.
Study groups P-VALUE post-hoc P-value
CRP (n ¼ 39) CRS (n ¼ 41) Control (n ¼ 41) CRP/CRS CRP/Control CRS/Control
Mean ± SD Mean ± SD Mean ± SD
BMI (Kg/m2) Before 31.22 ± 3.88 31.28 ± 3.74 28.64 ± 5.78 0.014c 0.99 0.05 0.04
After 30.53 ± 3.79 30.32 ± 3.68 29.00 ± 5.94 0.273c e e e
%change 2.15 ± 2.78 3.01 ± 3.46 þ1.18 ± 2.30 <0.001c 0.42 <0.001* <0.001*
P a <0.001 <0.001 0.005
Median (IQR) Median (IQR) Median (IQR)
Edema Volume (mm3) Before 440 (460) 440 (560) 450 (400) 0.967b e e e
After 400 (440) 320 (420) 480 (580) 0.147b e e e
% change 28.57 (46) 29.72 (42.31) 22.72 (27.72) 0.531b e e e
P a 0.001 <0.001 0.225
Total LLIS Before 0.24 (0.23) 0.24 (0.22) 0.28 (0.19) 0.126b e e e
After 0.15 (0.16) 0.12 (0.21) 0.25 (0.18) <0.001b 0.84 0.001* 0.001*
%change 28.57 (56.6) 39.53 (50.2) 1.58 (11.42) 0.002b 0.436 0.011* 0.001*
P a 0.225 0.005 0.259
Physical LLIS Before 0.22 (0.15) 0.25 (0.28) 0.31 (0.19) 0.052b e e e
After 0.13 (0.15) 0.19 (0.19) 0.22 (0.22) 0.003b 0.186 0.034 <0.001*
%change 40.90 (45.64) 42.10 (62.5) 19.23 (83.72) 0.026b 0.534 0.031 0.005*
P a <0.001 <0.001 0.051
Psycho social LLIS Before 0.19 (0.28) 0.13 (0.25) 0.25 (0.25) 0.029b 0.791 0.04 0.041
After 0.06 (0.25) 0.06 (0.19) 0.25 (0.25) <0.016b 0.447 <0.001* 0.001*
%change 21.8 (72.21) 23.53 (60.31) 36.22 (107.56) 0.056b e e e
P a 0.001 0.010 0.705
Functional LLIS Before 0.25 (0.3) 0.25 (0.24) 0.40 (0.3) 0.121b e e e
After 0.15 (0.15) 0.15 (0.29) 0.35 (0.3) 0.003b 0.692 0.001* 0.006*
%change 25 (66.63) 36.36 (60) 10 (63.28) 0.007b 0.487 0.014* 0.005*
P a 0.260 <0.001 0.260
*Significant pairwise comparison in Post hoc analysis (According to Bonferroni correction, the P-value will be significant if a is lower than 0.016).
% Change was calculated as [absolute change]/[baseline value]*100.
a Wilcoxon signed-rank test.
b Kruskal-Wallis test.
c one-way ANOVA.
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There was a significant difference between groups in BMI value
before the intervention (P ¼ 0.014), and its changes during the
study (P < 0.001). Post hoc analysis showed that this significant
difference was due to a higher BMI decrease in CRP (2.15%) and CRS
(3.01%) compared to a 1.18% increase of BMI in the Control group.
Edema volume decreased significantly in CRP (28.57%; P ¼ 0.001)
and CRS (29.72%; P < 0.001) groups compared to the beginning of
the study. But there was no significant difference between the
study groups. (P ¼ 0.531).
As mentioned before, because of the longitudinal nature
response data, we used the marginal modelling methodology with
the GEE approach to compare the mean trend of edema volume,
BMI, and LLIS in intervention and control groups (Table 4). In
studying the trend of quality of life during the intervention time in
three groups, the effect of baseline BMI, the percentage change of
BMI, and edema volume were adjusted. For each response variable,
if there was no statistically significant difference among the three
groups at the baseline, the group (intervention) variable was not
included in the marginal model. The results of this analysis
demonstrated that the CRS and CRP groups had a significant dif-
ference compared to the control group regarding the mean total
(P ¼ 0.004 for CRS; P ¼ 0.012 for CRP), psychosocial (P ¼ 0.022 for
CRS; and P ¼ 0.009 for CRP), and functional (P ¼ 0.002 for CRS, and
P ¼ 0.003 for CRP) LLIS scores. The edema volume had a higher
decrease in the CRS group compared to the control (P ¼ 0.002). In
addition, a greater reduction in BMI could be observed in CRS
(P < 0.001) and CRP groups (P < 0.001) compared to the control
group (Table 4).
Furthermore, the results of contrast analysis showed no signif-
icant difference between the CRS and CRP groups regarding themean trend of BMI (P¼ 0.39) and edema volume (P¼ 0.389) as well
as the mean total (P ¼ 0.682), physical (P ¼ 0.343), psychosocial
(P ¼ 0.698), and functional (P ¼ 0.917) LLIS scores.4. Discussion
To the best of our knowledge, the present study is the first
randomized clinical trial investigating the effect of synbiotic sup-
plementation along with a low-calorie diet in patients with BCRL.
The results indicate that a low-calorie diet supplemented with
synbiotics significantly decreased the quality of life impairment as
well as edema volume and BMI. Furthermore, a more considerable
improvement in trial outcomes was observed following a low-
calorie diet plus synbiotics compared to those that had followed a
low-calorie diet alone. However, the differences between the two
intervention groups were not statistically significant.
The present study was performed on 121 women with breast
cancer-induced lymphedema. There was no statistical difference in
demographic and clinical characteristics between the study groups
except for those receiving chemotherapy. This data insists on the
strength of the study in eliminating assignment bias of participants
to groups by randomization. Coincidentally, the BMI showed a
significant difference between the study groups in the baseline,
which adjusted its effect on the analysis.
Quality of life improved significantly by 39.53%, 28.57%, and 1.5%
in CRS, CRP, and control groups, respectively. indicating that the
intervention, which was mostly low-calorie diet, was able to
improve the total quality of life of these patients significantly.
Although there was no significant difference in improving the
quality of life between CRS and CRP groups (P ¼ 0.84), the effect
was higher in the group receiving synbiotic supplementation along
Table 4
The GEE results for comparing the mean trend of Edema Volume, BMI, LLIS and its subscales in intervention and control groups.
Dependent variable Independent Variable Beta Standard Error P-value
Edema volumea Intercept 606.92 38.44 <0.001
Time 50.76 37.20 0.172
CRP*time 92.24 56.10 0.105
CRS*time 135.13 45.31 0.002
BMI Intercept 28.64 0.89 <0.001
Time 0.36 0.10 <0.001
CRP*time 1.04 0.17 <0.001
CRS*time 1.32 0.20 <0.001
Total LLIS b Intercept 0.26 0.08 0.001
Time 0.02 0.03 0.362
CRP*time 0.07 0.03 0.012
CRS*time 0.08 0.03 0.004
Physical LLIS b Intercept 0.30 0.02 <0.001
Time 0.12 0.03 <0.001
CRP*time 0.03 0.04 0.356
CRS*time 0.07 0.04 0.058
Psychosocial LLIS b Intercept 0.23 0.09 0.009
Time 0.03 0.03 0.394
CRP*time 0.09 0.04 0.009
CRS*time 0.08 0.04 0.023
Functional LLIS b Intercept 0.50 0.11 <0.001
Time 0.15 0.02 <0.001
CRP*time 0.10 0.03 0.003
CRS*time 0.10 0.03 0.003
GEE analysis compares the changes of study outcomes in each intervention arm (intervention arm * time interaction) with the control (as the reference group), adjusted for
variable factors.
Significant correlations (P < 0.05) are shown in bold text.
Abbreviations: GEE, generalized estimating equations; LLIS, lymphedema life impact scale.
a Adjusted for % BMI change.
b Adjusted for baseline BMI, % BMI change, and % edema volume change.
S. Vafa et al. / The Breast 54 (2020) 37e45 43with a low-calorie diet compared to the group receiving the low-
calorie diet alone (39.53% vs 28.57%). The higher dose of synbiotic
supplement or longer follow-up duration may affect this difference
of estimation and can be evaluated in future researches. Due to
ethical issues and limited studies in this field [32,33], we could not
include a separate group that had just received synbiotic supple-
mentation, which could clarify the independent effect of synbiotic
on quality of life. According to the results of this study and lack of
side effects, it seems that the effect of synbiotics alone can be
assessed in the next study.
The results of this study demonstrated that the edema volume
decreased by 29.72% in the CRS group and 28.57% in the CRP group.
However, this difference between the study groups was not sig-
nificant. But, by adjusting the effect of BMI changes as a confounder
in edema volume, we found that the edema volume in the group
who received synbiotic supplementation along with a low-calorie
diet decreased significantly compared to the control group. Since
lymphedema is an inflammatory disease [34,35], synbiotics by
exerting their anti-inflammatory effects [36,37] can reduce
inflammation and subsequently reduce the volume of edema in
these people.
Furthermore, BMI was significantly reduced by 3.01% in the CRS
group and 2.15% in the CRP group compared to the control, and this
may correlate with a better quality of life. Arikawa [38] and wah-
nefried [39] in different studies approved the improved quality of
life in breast cancer survivors following a weight loss. It seems that
weight loss is so effective in these patients that it is better to be
included in the lymphedema treatment protocols. Also, since the
lymphatic system moves fluid, macromolecules, and formed ele-
ments fromwithin the interstitial spaces into initial lymphatics and
to pre collectors and collectors, the liquids intake in weight loss
diets is very important.
After adjusting the interaction effect of intervention and time on
the study outcomes, we observed that the total quality of life and itsPsychosocial and functional subgroups improved significantly
compared to the control group in both groups of receiving a low-
calorie diet with or without synbiotic supplementation. Adjusting
important confounders of this correlation persists in the marginal
effect of a low-calorie diet on the quality of life of lymphedema
patients.
The possible mechanisms underlying the favourable effects of
synbiotics on quality of life in patients with cancer are not fully
understood yet. Synbiotics could modulate the gut microbiota,
inhibit the production of proinflammatory cytokines and cell pro-
liferation. Besides, it exerts cytotoxic effect against cancer cells
[40,41], which consequently may lead to amelioration of the
physical and functional impairments related to the BCRL. Further-
more, it has been shown that synbiotics could stimulate the pro-
duction of molecules with neuroactive properties, including short-
chain fatty acids (SCFAs) and brain-derived neurotrophic factor
(BDNF). They may influence behavior, emotion, and cognition
through the stimulatory effect on neurogenesis, the biosynthesis of
serotonin, and neuronal survival and differentiation; while they
could suppress the neuroinflammation [42,43]. Due to such neu-
roprotective properties, they might relieve psychological symp-
toms related to the lymphedema and contribute to the improved
quality of life in BCRL patients.
We assumed that the quality of life in these patients might have
improved due to BMI and edema volume changes, so we adjusted
for these two important confounders of quality of life in lymphe-
dema, and surprisingly we found that quality of life in both inter-
vention groups compared to control remained significant. This
indicates the importance of low-calorie diet in these patients
because these are often involved inweight gain, so, if we reduce the
BMI, we can improve the quality of life in these patients. Since the
most critical goal of lymphedema treatment is to decrease the
patients’ quality of life disturbance, including a dietary consultant
in their edema reduction protocol, can improve the outcome.
S. Vafa et al. / The Breast 54 (2020) 37e4544This study adds novel and relevant findings to the scientific
body of knowledge regarding the efficacy of a combination of
synbiotic and low-calorie diet as the adjuvant therapy in the
management of post-treatment complications of breast cancer.
5. Conclusion
In summary, this randomized, placebo-controlled clinical trial
showed that daily supplementation of synbiotics plus a low-calorie
diet for ten weeks caused a significant improvement in the quality
of life, edema volume, and BMI. Therefore, adding low-calorie
diet along with synbiotics supplement to the treatment protocols
used is recommended for overweight and obese breast cancer
survivors with lymphedema.
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